Yi Zhe Wang
Plus aucun poste en cours
Fortune : - $ au 30/04/2024
Profil
Yi Zhe Wang served as the Chief Executive Officer & Director at LianBio from 2021 to 2023.
Prior to that, he was the Senior VP-BioMedicines & Oncology Businesses at Lilly China Research & Development Co. Ltd.
from 2018 to 2020.
Wang holds a doctorate from Yale University, an undergraduate degree from Ramapo College of New Jersey, and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LIANBIO
-.--% | 10/04/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Anciens postes connus de Yi Zhe Wang
| Sociétés | Poste | Fin |
|---|---|---|
| LIANBIO | Directeur Général | 16/12/2023 |
Lilly China Research & Development Co. Ltd.
 Lilly China Research & Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Lilly China Research & Development Co., Ltd. is a Chinese company that engages in the discovering and developing of diabetes medicines. The company is based in Shanghai, China. | Corporate Officer/Principal | 01/05/2020 |
Formation de Yi Zhe Wang
| Yale University | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Ramapo College of New Jersey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LIANBIO | Health Technology |
| Entreprise privées | 1 |
|---|---|
Lilly China Research & Development Co. Ltd.
Lilly China Research & Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Lilly China Research & Development Co., Ltd. is a Chinese company that engages in the discovering and developing of diabetes medicines. The company is based in Shanghai, China. | Health Technology |
